NDASUBCUTANEOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
6/8 — Strong
TYMLOS (abaloparatide) by Radius Health. Approved for osteoporosis. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYMLOS (abaloparatide) is a subcutaneous solution approved in April 2017 for the treatment of postmenopausal osteoporosis. It is a parathyroid hormone-related peptide (PTHrP) analog that works by stimulating osteoblast activity to increase bone formation and mineral density. TYMLOS represents an alternative mechanism to traditional bisphosphonates and denosumab in the osteoporosis treatment armamentarium, targeting patients seeking anabolic bone-building therapy.
$0.2BPart D
13.7 years to LOEMechanism of Action
Pharmacologic Class:
Parathyroid Hormone-Related Peptide Analog
Indications (1)
Clinical Trials (14)
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Started Jun 2025
282 enrolled
Postmenopausal Women With Osteoporosis
Supracondylar Distal Femur Fractures and Abaloparatide
Started Jun 2024
0Femoral Fractures
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Started Jul 2021
22,054 enrolled
Osteoporosis, Postmenopausal
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Started Feb 2021
70 enrolled
Osteoporosis, Postmenopausal
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.
Started Nov 2020
36 enrolled
Osteoporosis
Worked on TYMLOS at Radius Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.